Research Analysts Offer Predictions for LRMR FY2025 Earnings

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Analysts at Lifesci Capital issued their FY2025 earnings estimates for Larimar Therapeutics in a research report issued on Tuesday, February 24th. Lifesci Capital analyst F. Brisebois anticipates that the company will post earnings per share of ($1.70) for the year. Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share. Lifesci Capital also issued estimates for Larimar Therapeutics’ Q4 2025 earnings at ($0.41) EPS.

LRMR has been the topic of a number of other research reports. Citigroup boosted their price objective on Larimar Therapeutics from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Larimar Therapeutics in a report on Thursday, January 22nd. Leerink Partners raised shares of Larimar Therapeutics to a “strong-buy” rating in a research report on Monday, January 5th. Finally, Wedbush restated an “outperform” rating and set a $11.00 price objective on shares of Larimar Therapeutics in a research report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Larimar Therapeutics has a consensus rating of “Buy” and an average price target of $16.14.

Larimar Therapeutics Price Performance

LRMR stock opened at $5.31 on Thursday. The business has a 50 day simple moving average of $3.56 and a 200-day simple moving average of $3.80. The firm has a market capitalization of $439.55 million, a PE ratio of -2.75 and a beta of 1.00. Larimar Therapeutics has a 1 year low of $1.61 and a 1 year high of $6.42.

Institutional Trading of Larimar Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. AQR Capital Management LLC acquired a new position in Larimar Therapeutics in the first quarter valued at about $241,000. Acadian Asset Management LLC acquired a new stake in shares of Larimar Therapeutics during the first quarter valued at about $113,000. Rhumbline Advisers raised its stake in shares of Larimar Therapeutics by 15.7% in the 1st quarter. Rhumbline Advisers now owns 65,018 shares of the company’s stock valued at $140,000 after acquiring an additional 8,818 shares during the period. CWM LLC lifted its holdings in shares of Larimar Therapeutics by 205.0% in the 2nd quarter. CWM LLC now owns 32,652 shares of the company’s stock worth $94,000 after acquiring an additional 21,948 shares during the last quarter. Finally, Ethic Inc. purchased a new position in shares of Larimar Therapeutics during the 2nd quarter worth approximately $187,000. 91.92% of the stock is owned by institutional investors and hedge funds.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.